Updated Jan. 7, 2022

Find clinical guidance from the National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), AMA and other health and medical research organizations.

COVID-19 therapeutics can be used to prevent or treat eligible  patients who have tested positive for COVID-19 and have mild to moderate symptoms. Prevention and early treatment for eligible patients can help improve patient outcomes, reduce stress on health care facilities, and save lives.

FDA emergency use authorization (EUA)

In December 2021, the U.S. Food and Drug Administration (FDA) issued an EUA for Merck’s molnupiravir and Pfizer’s Paxlovid for the treatment of mild-to-moderate COVID-19 in adults with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19. 

Post-COVID conditions are a wide range of new, returning, or ongoing health problems people can experience four or more weeks after first being infected with the virus that causes COVID-19. Even people who did not have COVID-19 symptoms in the days or weeks after they were infected can have post-COVID conditions.

Multisystem inflammatory syndrome (MIS) can affect children (MIS-C) and adults (MIS-A). MIS is a rare but serious condition associated with COVID-19 in which different body parts become inflamed, including the heart, lungs, kidneys, brain, skin, eyes or gastrointestinal organs.

More information is available from the CDC.

Active State Undo
104
Featured Stories